论文部分内容阅读
日本厚生省的“E64开发研究班”新研制出了对Duchenne 型进行性肌萎缩症有希望的新药。据说,正因为是疑难病症,从前多次的药物疗效都被否定了、日本约有二至三千本病患者,这种新药的开发将给他们带来福音。据今堀班长透露,这种药被命名为 Roxostatin,是人工合成的与某一种酶的代谢物相似的物质。该研究班从前年五月开始,在国立疗养所下志津医院等四个医疗设施中,对十岁左右的73名 Duchenne型进行性肌营养障碍症患者进行治疗试验。每日,按1kg 体重4～8mg 的比例,经口服用此药后,对患者进行握力、站立动作、步行、上下楼梯和血液检验等综合判定,然后就服药前后的情况进行比较。
Japan’s Ministry of Health, “E64 Development Research Class” has developed a new drug Duchenne type of progressive muscular dystrophy promising. It is said that precisely because it is a difficult illness, many times before the efficacy of drugs have been denied, Japan, about two to three thousand patients, the development of this new drug will bring them good news. According to the monitor of Kyobo today, the drug is named Roxostatin and is a synthetic substance similar to the metabolite of a certain enzyme. The research class began treatment trials of 73 Duchenne-type patients with progressive muscular dystrophy at the age of 10 in four medical facilities, including the National Institute of Health, Shizu Hospital, from the previous May. Daily, according to 1kg weight 4 ~ 8mg ratio, after oral administration of the drug, the patient grip, standing movements, walking, stairs and blood tests and other comprehensive judgment, and then compared before and after taking the medication.